UroGen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a $25.00 price objective on the stock.

A number of other research firms have also recently weighed in on URGN. HC Wainwright restated a "buy" rating and issued a $60.00 price target on shares of UroGen Pharma in a report on Tuesday, October 15th. Oppenheimer restated an "outperform" rating and set a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, UroGen Pharma currently has a consensus rating of "Buy" and a consensus target price of $43.70.

UroGen Pharma Stock Up 2.2 %

UroGen Pharma stock traded up $0.23 during trading on Wednesday, reaching $10.77. The stock had a trading volume of 236,525 shares, compared to its average volume of 309,246. The stock has a market cap of $252.56 million, a PE ratio of -3.42 and a beta of 1.08. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 52-week low of $9.78 and a 52-week high of $20.70. The business has a 50 day moving average price of $10.82 and a 200 day moving average price of $12.32.

Insider Buying and Selling

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On UroGen Pharma

Large investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC purchased a new stake in shares of UroGen Pharma during the 4th quarter valued at about $14,608,000. Northern Trust Corp lifted its stake in shares of UroGen Pharma by 8.1% during the fourth quarter. Northern Trust Corp now owns 310,074 shares of the company's stock worth $3,302,000 after buying an additional 23,345 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of UroGen Pharma by 178.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 37,486 shares of the company's stock worth $399,000 after acquiring an additional 24,006 shares during the period. Aquatic Capital Management LLC purchased a new stake in shares of UroGen Pharma during the fourth quarter worth about $101,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in UroGen Pharma during the 4th quarter valued at about $208,000. Institutional investors own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.